Phase III clinical trial - Appareil pulmonaire

This randomized, multicenter, Phase 3 study will compare the efficacy and safety of combining;amivantamab and lazertinib (Arm A) versus single-agent osimertinib (Arm B) as first-line treatment in;participants with EGFR-mutated locally advanced or metastatic NSCLC not amenable to curative therapy.;Combining amivantamab and lazertinib may lead to improved treatment outcomes through synergistic;anti-EGFR activity, prevention of EGFR- or MET-based resistance to a third-generation EGFR TKI, and;potential recruitment of Fc-bearing immune cells in the anti-tumor response. The contribution of;amivantamab to the activity of the combination will be assessed by comparing the efficacy observed in the;amivantamab and lazertinib combination arm (Arm A) with that in a lazertinib monotherapy arm (Arm C).